17 March 2015Americas
Actavis completes $71bn acquisition of Allergan
Dublin-based pharmaceutical company Actavis has completed its acquisition of Allergan for $71 billion.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
11 September 2017 Allergan has transferred its patent rights for a dry eye treatment to a Native American tribe, in a bid to obtain immunity against an inter partes review (IPR).
Americas
19 September 2017 Earlier this month, in a bid to obtain immunity against an inter partes review (IPR), Allergan transferred its patent rights for a dry eye treatment to a Native American tribe.
Big Pharma
15 June 2021 Allergan subsidiary Forest Laboratories will have to argue its case before a jury over claims that it used pay-for-delay deals to keep generic copies of blockbuster Alzheimer drug, Namenda, from the marketplace.
Editor's picks
Editor's picks
Americas
11 September 2017 Allergan has transferred its patent rights for a dry eye treatment to a Native American tribe, in a bid to obtain immunity against an inter partes review (IPR).
Americas
19 September 2017 Earlier this month, in a bid to obtain immunity against an inter partes review (IPR), Allergan transferred its patent rights for a dry eye treatment to a Native American tribe.
Big Pharma
15 June 2021 Allergan subsidiary Forest Laboratories will have to argue its case before a jury over claims that it used pay-for-delay deals to keep generic copies of blockbuster Alzheimer drug, Namenda, from the marketplace.
Americas
11 September 2017 Allergan has transferred its patent rights for a dry eye treatment to a Native American tribe, in a bid to obtain immunity against an inter partes review (IPR).
Americas
19 September 2017 Earlier this month, in a bid to obtain immunity against an inter partes review (IPR), Allergan transferred its patent rights for a dry eye treatment to a Native American tribe.
Big Pharma
15 June 2021 Allergan subsidiary Forest Laboratories will have to argue its case before a jury over claims that it used pay-for-delay deals to keep generic copies of blockbuster Alzheimer drug, Namenda, from the marketplace.